We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Verona Pharma Plc | LSE:VRP | London | Ordinary Share | GB00BYW2KH80 | ORD 5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 55.00 | 45.00 | 65.00 | - | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
20/1/2017 14:27 | thebossman The clue was in what you have copied above from 23 November :- 'The number of shares and price of the proposed offering [on Nasdaq] have not yet been determined.' So now, in January, having determined the price thought necessary for a Nasdaq listing, a consolidation is proposed to take place on AIM to match the proposed US price. The company clearly had this option in mind taking into account what was said on the 23rd of November 2016 - even though no outright mention was made of any consolidation - the possibility was clearly there. | vasilis | |
20/1/2017 12:43 | Iv just been looking at the RNS for the 23/11/2016 so where in the 23/11/2016 rns does it mention/state a 50 for 1 share offer..I know i wear specs but im not blind etc.. Prior to undertaking the Global Offering, and in order to achieve an appropriate listing price for the American depositary shares, the Company proposes to undertake a consolidation of every 50 ordinary shares of GBP0.001 each in issue at 6.00 p.m. on 10 February 2017 into one ordinary share of GBP0.05 each (the "Consolidation"). As at 17 January 2017, the Company had 2,568,053,160 ordinary shares in issue, each with a nominal value of GBP0.001. PR Newswire London, November 23 THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014 Verona Pharma Plans to Conduct Registered Initial Public Offering in the U.S. November 23, 2016, Cardiff � Verona Pharma plc (AIM: VRP) today announced that it plans to conduct a registered initial public offering in the United States. The number of shares and price of the proposed offering have not yet been determined. The proposed offering is expected to commence in the first half of 2017, after the U.S. Securities and Exchange Commission completes its review process of the registration statement relating to the proposed offering and subject to market and other conditions. This press release is being made pursuant to and in accordance with Rule 135 under the Securities Act of 1933, as amended. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction. Forward Looking Statements This press release contains forward-looking statements. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our plans to conduct a registered initial public offering in the United States and the timing of the proposed offering.� These forward-looking statements are based on management�s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from our expectations expressed or implied by the forward-looking statements, including, but not limited to, the following: we may determine not to conduct a registered initial public offering in the time frame that we currently expect or at all, due to a number of potential important factors, including conditions in the U.S. capital markets, negative global economic conditions, potential negative developments in our clinical trials or research programs, other negative developments in our business, or unfavorable legislative or regulatory developments. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management�s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release. -Ends- For further information please contact: Verona Pharma plc Tel: +44 (0)20 3283 4200 Jan-Anders Karlsson, Chief Executive Officer N+1 Singer Tel: +44 (0)20 7496 3000 Aubrey Powell / Jen Boorer FTI Consulting Tel: +44 (0)20 3727 1000 Simon Conway / Stephanie Cuthbert / Natalie Garland-Collins | thebossman | |
18/1/2017 08:43 | Tim.i know but play the game small investors always lose out to the money men.All well and good if the Sp opens @4 or 5 bucks.And not at the planned 2 bucks. | thebossman | |
18/1/2017 07:53 | >>>bossman I suspect the main reason for the consolidation is to assist with the Nasdaq listing. Apparently US investors much prefer shares denominated in dollars rather than cents. | timbo003 | |
18/1/2017 07:21 | 50 Of mine for 1 new share.Same old story then... | thebossman | |
11/1/2017 22:51 | yes more professional website. I reckon this may be a very exciting first quarter. That's what my bank manager is hoping for anyhow. | shakin not stirred | |
10/1/2017 08:55 | Thanks bewise2 A better focussed and more 'businesslike' website. I wonder if the anticipated IPO in the USA has prompted this revamp? Note also the London address is given which would also be more attractive to USA investors. | vasilis | |
09/1/2017 20:36 | Vrp has a new website...take a look guys :) | bewise2 | |
04/1/2017 17:25 | It may simply be that she had to exercise her options upon leaving the company, as it may be a condition of holding the options that you are an employee? (I don't know if that's the case, but it's certainly a possibility.) | lord buffett | |
03/1/2017 13:43 | lets hope she does not. Otherwise not looking too good for her confidence in RPL554 | shakin not stirred | |
29/12/2016 18:49 | Wouldn't be surprised if Kathy didn't cash in her 2m shares now she's gone. | ewads | |
21/12/2016 09:50 | Having read the posts prior to there removal from VRP LSE board.It would suggest that your paraphrasing of the famous line from Casablanca might be very appropriate. No doubt see an uplift in share price in 2017. " of all the COPD lab jpoints in all the towns in all the world GSK walk into VRP or visa versa?? | shakin not stirred | |
20/12/2016 10:11 | Vasilis I hope you are correct in your paraphrase. | shakin not stirred | |
19/12/2016 13:58 | Must be due at least 3 rns in New Year. With reference to CF trials. Kathys replacement. USA listing. But which order. Can think of another RNS but will wait and see. All have a fabulous Christmas and PROSPEROUS 2017 or 2018 if invested here. | shakin not stirred | |
19/12/2016 13:51 | Let us hope that all our patents are water tight else Verona Pharma have just given a massive boost to GSK which would be quite disadvantageous for us investors. However the institutional investors I presume are fully aware of Kathy's move to GSK and seem unperturbed as no big sells and I have to presume they have an ear of the hierarchy in Verona? | shakin not stirred | |
16/12/2016 10:58 | Good spot Vas (and Mol). Reassuring to know that RPL554 is definitely now on GSK's radar screen. I wonder who will replace Kathy at Verona? | timbo003 | |
16/12/2016 09:38 | Grateful to mol42 for picking this up on the II BB :- As you can see, Kathy was with Verona for nearly 4 years in a number of different roles and was involved with the development of the new suspension formula of RPL554 as well as the IP filings and has now moved to GSK as from last month. Presumably GSK made her an 'offer she couldn't refuse', but more significantly for us is the fact that Kathy probably knows more about the new formulation of RPL554 than anyone else outside of Verona Pharma. However, whether or not her 'inside knowledge' of RPL554 was a factor or not in her getting her new job at GSK remains to be seen. | vasilis | |
08/12/2016 18:00 | Whats the pros and cons of a USA float for shareholders? | francis55 | |
02/12/2016 07:08 | Friday 02 December, 2016 GlaxoSmithKline PLC Relvar Ellipta approved in Japan for COPD RNS Number : 7952Q GlaxoSmithKline PLC 02 December 2016 | thebossman | |
23/11/2016 10:27 | I hope the US listing goes somewhat better than it did for Motif Bio (MTFB), which was a disaster as far as the share price was concerned | timbo003 | |
23/11/2016 10:13 | Got to think that the US valuation will be a much higher one than a UK centric one -based on its potential. For various reasons many US funds prefer to buy US listed. Currency might be one factor. | meijiman | |
23/11/2016 09:47 | Cracking RNS, onwards and upwards....everythin | bewise2 | |
23/11/2016 09:42 | surely this shows that the team think they have a great product why wold you do this with the costs involved if it was to fail its clinicals ? discuss | oldvic |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions